Clinical TrialID 6659

Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers

NCT00498979

Stage IV Melanoma

Back to Browse

Relationship Network

Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.

Click a node to open it in a new tab
Trial: 1Ingredient: 1Links: 1
Arranging relationship network...

Record Fields

Scalar fields from the final clinical_trial record.

Clinical Trial Id
6659
Evidence Id
6659
Core Evidence Id
6659
Source Clinical Trial Id
6645
Herb2 Clinical Trial Id
HBCT006645
Nct Id
NCT00498979
Title
Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers
Status
Completed
Phase
Phase 1
Study Result
No
Study Condition
Stage IV Melanoma
Study Type
Interventional
Study Design
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
Intervention
BIOLOGICAL: recombinant interferon alfa-2b|DRUG: cisplatin|DRUG: sodium stibogluconate|DRUG: dacarbazine|DRUG: vinblastine
Intervention Allocation
Intervention Model
Single_Group
Intervention Mask
Intervention Purpose
Treatment
Gender
All
Age
Adult, Older_Adult
Enrollment
22
Outcome Measure
Safety of the combination of sodium stibogluconate and interferon alfa-2b with chemotherapy, 2 years
Sponsor Collaborator
Case Comprehensive Cancer Center|National Cancer Institute (NCI)
Funded By
OTHER
Location
Cleveland Clinic Taussig Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, 44195, United States
Other Id
CASE3Y06
Start Date
2007-05
Primary Completion Date
2010-05
Completion Date
2012-01
First Posted
2007-07-11
Results First Posted
Last Update Posted
2020-07-24
Study Document
Study Url
https://clinicaltrials.gov/study/NCT00498979
Title Cn
Title En
Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers
Bilingual Status
semi_complete